Develops antibody therapies for cancer and autoimmune diseases, focusing on innovative biologics and precision medicine.
MorphoSys AG is a biopharmaceutical company operating at the commercial stage, specializing in the discovery, development, and commercialization of therapeutic antibodies for cancer and autoimmune diseases across the United States. Among its prominent offerings is Tafasitamab, an antibody designed to treat B cell malignancies such as diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company's robust pipeline includes Pelabresib, a small molecule currently undergoing Phase II clinical trials for myelofibrosis treatment, and Felzartamab, an antibody targeting CD38 in Phase I/II trials for anti-PLA2R-positive membranous nephropathy.
MorphoSys AG also focuses on advancing CPI-0209, a Phase I/II small molecule aimed at enhancing anti-tumor activity by inhibiting EZH2. Collaborative efforts include partnerships with pharmaceutical leaders for the development of Gantenerumab for Alzheimer's disease, Otilimab for rheumatoid arthritis, Tremfya for psoriasis and related conditions, and MOR210/TJ210 for immuno-oncology and autoimmune disorders.
Founded in 1992 and headquartered in Planegg, Germany, MorphoSys AG has established regional licensing agreements with I-Mab Biopharma for felzartamab in China, Taiwan, Hong Kong, and Macau. The company also maintains strategic alliances with LEO Pharma and a joint collaboration with Incyte Corporation and Xencor, Inc. to investigate combination therapies involving tafasitamab, plamotamab, and lenalidomide for relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma. MorphoSys AG continues to innovate in biopharmaceuticals, striving to advance therapies that address critical medical needs worldwide.